Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally.
The last earnings update was 282 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Esperite is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Esperite has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Esperite. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Esperite's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to compare the PB ratio to the industry average as no data exists.
Examine Esperite's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Esperite's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Esperite has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Esperite's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Esperite's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Esperite's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Esperite is high growth as no earnings estimate data is available.
Unable to determine if Esperite is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Esperite's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Frédéric A. Amar has been Chief Executive Officer and Executive Director of Esperite N.V. (Formerly Cryo-Save Group N.V.) since March 19, 2014 and served as its Non Executive Director since November 2013. Mr. Amar served as a Non-Executive Director at Cryo-Save Group N.V. until March 19, 2014. Mr. Amar has a strong scientific background and a successful track record creating and managing companies. He founded ATelecom S.A. in November 2011 in 1995. He also founded Salveo Biotechnology S.A. in November 2011. Mr. Amar holds a degree in Crystallography and a degree in Pharmacy (Pharm.D.) from the Université de Pharmacie of Marseille.
No earnings data for Esperite, not possible to compare to compensation.
Frédéric's remuneration is lower than average for companies of similar size in Germany.
CEO & Executive Director
Chief Technical Officer of Indian region
Head of IT
Xi Tong Li
Head of Bioinformatics
Chief Operating Officer of CryoSave
Finance & Tax Manager
Genetics Product Manager
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Esperite board of directors is about average.
Board of Directors
Gert-Jan van der Marel
CEO & Executive Director
Ronald H. Lorijn
Member of the Scientific Advisory Board
Vincent M. Borgeot
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord. It also provides proteomics and genomics predictive medicines; and implements its proprietary technology for clinical grade production of autologous mesenchymal and stromal stem cells. In addition, it develops AGAATA, a diagnostic system based on the next generation sequencing technology, as well as allows laboratories to perform their own genetic analysis with the bioinformatics and methods developed by Genoma. The company’s products portfolio includes Tranquility, a non-invasive prenatal test; and Cryosave’s whole genome sequencing, carrier screening tests, and other products. Further, it engages in biobanking cord blood and cord tissue stem cells business. The company was formerly known as Cryo-Save Group N.V. and changed its name to Esperite N.V. in July 2014. Esperite N.V. was founded in 2000 and is headquartered in Amsterdam, the Netherlands.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.